Three Pathways have emerged in Innovative Access Agreements
The days of simply determining the market demand for a new drug as a function…
CertaraJune 11, 2021
Outcomes Based Agreements
The days of simply determining the market demand for a new drug as a function…
CertaraJune 11, 2021
Certara Acquires UK-based Insight Medical Writing
Expands global reach and deepens regulatory expertise PRINCETON, NJ.— June 10, 2021– Certara, Inc., the…
CertaraJune 10, 2021
Your First Choice in Complex Biologics Drug Development
The pharmaceutical has made massive investments in complex biologics, a drug class that includes oligonucleotide…
CertaraJune 1, 2021
De-risk your program with evidence-based secondary pharmacology insights
Safety issues account for about a quarter of the attrition in drug projects and can…
CertaraMay 28, 2021
Stakeholder perspectives: current and potential benefits
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 26, 2021
Strengths and opportunities for HTAs and market access in Europe through case studies
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 26, 2021
Similarities and differences between SNDS and other claim databases
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 25, 2021
Using Authoring Templates to Write the Right Way
Creating submission-ready regulatory documents that are consistent in presentation, appropriate in content, and formatted to…
CertaraMay 25, 2021
Overview of SNDS and the key working practices to access the database and ongoing SNDS developments
Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…
CertaraMay 25, 2021
